GlassScriptPhysician profile
Seth L Stephenson
NPI 1164778924
$45,474.52
in general payments reported to CMS, 2019-2025
30 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,290 · 2022: $3,698 · 2023: $12K · 2024: $16K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $15K · Consulting Fee: $1,125 · Education: $391 · Travel and Lodging: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,293.00 |
| Food and Beverage | $15,337.05 |
| Consulting Fee | $1,125.00 |
| Education | $390.86 |
| Travel and Lodging | $341.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25,972.98 | 2021-2025 | Otezla, Otezla, Amjevita |
| Abbvie INC. | $3,222.72 | 2021-2025 | |
| Janssen Biotech, INC. | $3,144.04 | 2021-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $1,654.42 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $1,494.54 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,357.47 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,337.26 | 2021-2025 | Cosentyx |
| E.R. Squibb & Sons, L.L.C. | $1,268.25 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $1,043.43 | 2021-2025 | |
| Ucb, INC. | $1,036.97 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $762.23 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $709.50 | 2023-2025 | Zoryve |
| Pfizer INC. | $436.39 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $428.98 | 2021-2023 | Tremfya |
| Galderma Laboratories, L.P. | $224.97 | 2021-2025 | Aklief, Oracea, Epsolay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.57 | 2021 | |
| Vyne Pharmaceuticals INC. | $209.02 | 2021 | |
| Dermavant Sciences, INC. | $203.62 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.88 | 2023-2024 | Spevigo |
| Medimetriks Pharmaceuticals, INC. | $98.93 | 2024 | Clindacin Etz |
| Leo Pharma INC. | $94.03 | 2022-2025 | Anzupgo, Adbry |
| Almirall LLC | $84.78 | 2021-2024 | Klisyri, Seysara |
| Epi Health, LLC | $68.13 | 2022 | |
| Mayne Pharma Commercial LLC | $64.93 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $41.42 | 2023-2024 | Ycanth |
| Krystal Biotech INC | $38.75 | 2023-2024 | Vyjuvek |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Lnhc, INC | $14.17 | 2025 | Zelsuvmi |
| Sanofi-Aventis U.S. LLC | $13.94 | 2021 | |
| Stemline Therapeutics INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.